Oral Semaglutide
OASIS 3
Novo Nordisk · Phase 3 · Completed · Enrollment 200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide 50 mg | Obesity or overweight | 50 mg | n/r | n/r | n/r |
| Semaglutide Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Oral Semaglutide
Novo Nordisk · Phase 3 · Completed · Enrollment 200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide 50 mg | Obesity or overweight | 50 mg | n/r | n/r | n/r |
| Semaglutide Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |